1. Extracellular Vesicles from Mesenchymal Stromal Cells for the Treatment of Inflammation-Related Conditions
- Author
-
Georges E. Grau, Xianting Ding, Christopher B. Little, Binbin Xia, Elham Hosseini-Beheshti, Sean Thomas Ryan, Lana McClements, Dinara Afrose, and Jiao Jiao Li
- Subjects
rheumatoid arthritis ,Inflammation ,Disease ,Review ,Bioinformatics ,Extracellular vesicles ,Models, Biological ,Catalysis ,Inorganic Chemistry ,preeclampsia ,lcsh:Chemistry ,0399 Other Chemical Sciences, 0604 Genetics, 0699 Other Biological Sciences ,Extracellular Vesicles ,cardiovascular disease ,Small animal ,medicine ,Animals ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Beneficial effects ,lcsh:QH301-705.5 ,Spectroscopy ,Chemical Physics ,business.industry ,Regeneration (biology) ,Organic Chemistry ,Mesenchymal stem cell ,Mesenchymal Stem Cells ,General Medicine ,Computer Science Applications ,Clinical trial ,osteoarthritis ,lcsh:Biology (General) ,lcsh:QD1-999 ,inflammation ,regeneration ,medicine.symptom ,business ,mesenchymal stromal cells ,extracellular vesicles ,Alzheimer’s disease - Abstract
Over the past two decades, mesenchymal stromal cells (MSCs) have demonstrated great potential in the treatment of inflammation-related conditions. Numerous early stage clinical trials have suggested that this treatment strategy has potential to lead to significant improvements in clinical outcomes. While promising, there remain substantial regulatory hurdles, safety concerns, and logistical issues that need to be addressed before cell-based treatments can have widespread clinical impact. These drawbacks, along with research aimed at elucidating the mechanisms by which MSCs exert their therapeutic effects, have inspired the development of extracellular vesicles (EVs) as anti-inflammatory therapeutic agents. The use of MSC-derived EVs for treating inflammation-related conditions has shown therapeutic potential in both in vitro and small animal studies. This review will explore the current research landscape pertaining to the use of MSC-derived EVs as anti-inflammatory and pro-regenerative agents in a range of inflammation-related conditions: osteoarthritis, rheumatoid arthritis, Alzheimer’s disease, cardiovascular disease, and preeclampsia. Along with this, the mechanisms by which MSC-derived EVs exert their beneficial effects on the damaged or degenerative tissues will be reviewed, giving insight into their therapeutic potential. Challenges and future perspectives on the use of MSC-derived EVs for the treatment of inflammation-related conditions will be discussed.
- Published
- 2021